Marc Suskin

Cooley advised Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma), a global pharmaceutical company focused on scientific and technological innovation, on its exclusive license agreement with Merck KGaA, Darmstadt, Germany for the commercialization in mainland China of SHR7280, an oral small-molecule gonadotropin-releasing hormone receptor antagonist, for indications including medical-assisted reproduction and gynecology.

Cooley has filed an amicus brief in Whole Woman’s Health v. Jackson, one of the two cases currently before the Supreme Court challenging Texas Senate Bill 8 (SB 8), an unprecedented attempt to nullify the federal constitutional right to receive an abortion recognized in Roe v. Wade and Planned Parenthood v. Casey. Lawyers Kathleen Hartnett, Adam Gershenson, Julie Veroff, Patrick Hayden, Kelsey Spector, Marc Suskin, Rachel Thorn and Alessandra Vittoria Rafalson led the Cooley effort.

Cooley advised Otsuka Pharmaceutical, a global healthcare company, on its worldwide collaboration and license agreement with biopharmaceutical company Sunovion Pharmaceuticals and parent company Sumitomo Dainippon Pharma for the joint development and commercialization of four novel candidate compounds. Lawyers Alison Freeman-Gleason and Brian Stalter led the Cooley team advising Otsuka.

Fate Therapeutics in its global collaboration and option agreement with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Under the multi-year collaboration agreement, Janssen will contribute proprietary antigen binding domains for up to four tumor-associated antigen targets. The Company will apply its iPSC product platform to research and preclinically develop new iPSC-derived chimeric antigen receptor (CAR) NK and CAR T-cell product candidates.

Under the terms of the agreement, Janssen will receive $50 million in cash and $50 million from the purchase by Johnson & Johnson Innovation  JJDC, Inc. of newly issued shares of the Company’s common stock at a price per share of $31.00. Janssen is also eligible to receive payments of up to  $1.8 billion upon the achievement of development and regulatory milestones and up to $1.2 billion upon the achievement of commercial milestones, plus double-digit royalties on worldwide commercial sales of products targeting the antigens.